

# World Journal of *Gastrointestinal Oncology*

*World J Gastrointest Oncol* 2024 December 15; 16(12): 4532-4781



**EDITORIAL**

- 4532 Mixed neuroendocrine non-neuroendocrine tumors: The quest for evidence  
*Cives M, Porta C, Palmirotta R*
- 4537 Is nutritional status a new indicator to use in clinical practice for colorectal cancer patients?  
*Berardi R, Chiariotti R, Menstrasti G*
- 4543 Gene targets with therapeutic potential in hepatocellular carcinoma  
*Shodry S, Hasan YTN, Ahdi IR, Ulhaq ZS*
- 4548 Estimating prognosis of gastric neuroendocrine neoplasms using machine learning: A step towards precision medicine  
*Wang HN, An JH, Zong L*
- 4553 Exploring Xiaojianzhong decoction's potential in gastric cancer treatment: Integrative insights and experimental validation  
*Cheng CH, Hao WR, Cheng TH*
- 4559 Critical considerations for the management of gastrointestinal mixed neuroendocrine non-neuroendocrine neoplasms and pure neuroendocrine carcinomas  
*Pavlidis ET, Galanis IN, Pavlidis TE*

**REVIEW**

- 4565 Unraveling the role of cancer-associated fibroblasts in colorectal cancer  
*Cui JY, Ma J, Gao XX, Sheng ZM, Pan ZX, Shi LH, Zhang BG*

**ORIGINAL ARTICLE****Case Control Study**

- 4579 Prognostic utility of gamma-glutamyl transpeptidase to platelet ratio in patients with solitary hepatitis B virus-related hepatocellular carcinoma after hepatectomy  
*Yang CK, Wei ZL, Shen XQ, Jia YX, Wu QY, Wei YG, Su H, Qin W, Liao XW, Zhu GZ, Peng T*

**Retrospective Cohort Study**

- 4597 Prognostic prediction models for postoperative patients with stage I to III colorectal cancer based on machine learning  
*Ji XL, Xu S, Li XY, Xu JH, Han RS, Guo YJ, Duan LP, Tian ZB*
- 4614 Local excision for middle-low rectal cancer after neoadjuvant chemoradiation: A retrospective study from a single tertiary center  
*Chen N, Li CL, Wang L, Yao YF, Peng YF, Zhan TC, Zhao J, Wu AW*

**Retrospective Study**

- 4625** Risk factors for hepatocellular carcinoma in cirrhosis: A comprehensive analysis from a decade-long study  
*Zhou DQ, Liu JY, Zhao F, Zhang J, Liu LL, Jia JR, Cao ZH*
- 4636** Prognosis of radiotherapy for esophageal cancer in elderly patients exceeding seventy-five years old  
*Hu LL, Rong F, Liu L, Zhang L, Zhang LL, Yang Q, Xia ZL, Wang H*
- 4650** Nomogram model based on  $\gamma$ -glutamyl transferase to albumin ratio predicts survival in hepatocellular carcinoma patients with transarterial chemoembolization treatment  
*Wu ZY, Li H, Chen JL, Su K, Weng ML, Han YW*
- 4663** Deep learning model combined with computed tomography features to preoperatively predicting the risk stratification of gastrointestinal stromal tumors  
*Li Y, Liu YB, Li XB, Cui XN, Meng DH, Yuan CC, Ye ZX*
- 4675** Temozolomide and capecitabine regimen as first-line treatment in advanced gastroenteropancreatic neuroendocrine tumors at a Latin American reference center  
*Cruz-Diaz WE, Paitan V, Medina J, Flores R, Haro-Varas J, Mantilla R, Castro-Oliden V*

**Basic Study**

- 4685** Vitamin D 1,25-Dihydroxyvitamin D<sub>3</sub> reduces lipid accumulation in hepatocytes by inhibiting M1 macrophage polarization  
*Luo WJ, Dong XW, Ye H, Zhao QS, Zhang QB, Guo WY, Liu HW, Xu F*
- 4700** Matrine promotes colorectal cancer apoptosis by downregulating shank-associated RH domain interactor expression  
*Zhou YC, Wang QQ, Zhou GYJ, Yin TF, Zhao DY, Sun XZ, Tan C, Zhou L, Yao SK*
- 4716** Enhancing the radiosensitivity of colorectal cancer cells by reducing spermine synthase through promoting autophagy and DNA damage  
*Guo YB, Wu YM, Lin ZZ*

**META-ANALYSIS**

- 4728** Efficacy and safety of transhepatic arterial chemoembolization with drug-loaded microspheres in unresectable primary liver cancer  
*Deng J, Mi YH, Xie L, Sun XX, Liu DH, Long HJ, He LY, Wu DH, Shang HC*

**CASE REPORT**

- 4738** Mixed pancreatic ductal adenocarcinoma and well-differentiated neuroendocrine tumor: A case report  
*Zhao X, Bocker Edmonston T, Miick R, Joneja U*
- 4746** Signet-ring cell carcinoma of the transverse colon in a 10-year-old girl: A case report  
*Lv L, Song YH, Gao Y, Pu SQ, A ZX, Wu HF, Zhou J, Xie YC*

**LETTER TO THE EDITOR**

- 4753** Combinations of lenvatinib and immune checkpoint inhibitors plus transarterial chemoembolization, is it the prime time for unresectable hepatocellular carcinoma?  
*Centrone N, Serrano Uson Junior PL*
- 4757** Advancing hepatocellular carcinoma treatment with hepatic arterial infusion chemotherapy  
*Caliskan Yildirim E, Ergun Y*
- 4762** Timely identification and treatment of uterine artery pseudoaneurysm after hysteroscopic procedures  
*Byeon H*
- 4766** Current efficacy of hepatic arterial infusion chemotherapy in hepatocellular carcinoma  
*Dias E Silva D, Borad M, Uson Junior PLS*
- 4770** Use of traditional Chinese medicine bezoars and bezoar-containing preparations in hepatocarcinoma  
*Li DH, Wen QE, Feng RQ, Qiao C, Tian XT*
- 4778** Crosslink among cyclin-dependent kinase 9, ATP binding cassette transporter G2 and Beclin 1 in colorectal cancer  
*Shao ZB, He K, Su YB, Shi Z*

**ABOUT COVER**

Editorial Board Member of *World Journal of Gastrointestinal Oncology*, Zilvinas Dambrauskas, MD, PhD, Professor, Department of Surgery and Institute for Digestive System Research, Lithuanian University of Health Sciences, Kaunas 50161, Lithuania. zilvinas.dambrauskas@lsmuni.lt

**AIMS AND SCOPE**

The primary aim of *World Journal of Gastrointestinal Oncology (WJGO, World J Gastrointest Oncol)* is to provide scholars and readers from various fields of gastrointestinal oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

*WJGO* mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal oncology and covering a wide range of topics including liver cell adenoma, gastric neoplasms, appendiceal neoplasms, biliary tract neoplasms, hepatocellular carcinoma, pancreatic carcinoma, cecal neoplasms, colonic neoplasms, colorectal neoplasms, duodenal neoplasms, esophageal neoplasms, gallbladder neoplasms, etc.

**INDEXING/ABSTRACTING**

The *WJGO* is now abstracted and indexed in PubMed, PubMed Central, Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Scopus, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2024 edition of Journal Citation Reports® cites the 2023 journal impact factor (JIF) for *WJGO* as 2.5; JIF without journal self cites: 2.5; 5-year JIF: 2.8; JIF Rank: 72/143 in gastroenterology and hepatology; JIF Quartile: Q3; and 5-year JIF Quartile: Q2. The *WJGO*'s CiteScore for 2023 is 4.2 and Scopus CiteScore rank 2023: Gastroenterology is 80/167; Oncology is 196/404.

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: *Si Zhao*; Production Department Director: *Xiang Li*; Cover Editor: *Jia-Ru Fan*.

**NAME OF JOURNAL**

*World Journal of Gastrointestinal Oncology*

**ISSN**

ISSN 1948-5204 (online)

**LAUNCH DATE**

February 15, 2009

**FREQUENCY**

Monthly

**EDITORS-IN-CHIEF**

Monjur Ahmed, Florin Burada

**EDITORIAL BOARD MEMBERS**

<https://www.wjgnet.com/1948-5204/editorialboard.htm>

**PUBLICATION DATE**

December 15, 2024

**COPYRIGHT**

© 2024 Baishideng Publishing Group Inc

**INSTRUCTIONS TO AUTHORS**

<https://www.wjgnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjgnet.com/bpg/GerInfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjgnet.com/bpg/gerinfo/240>

**PUBLICATION ETHICS**

<https://www.wjgnet.com/bpg/GerInfo/288>

**PUBLICATION MISCONDUCT**

<https://www.wjgnet.com/bpg/gerinfo/208>

**ARTICLE PROCESSING CHARGE**

<https://www.wjgnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjgnet.com/bpg/GerInfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>



## Crosslink among cyclin-dependent kinase 9, ATP binding cassette transporter G2 and Beclin 1 in colorectal cancer

Zhong-Bao Shao, Ke He, Yu-Bin Su, Zhi Shi

**Specialty type:** Oncology

**Provenance and peer review:**

Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review report's classification**

**Scientific Quality:** Grade B

**Novelty:** Grade B

**Creativity or Innovation:** Grade B

**Scientific Significance:** Grade B

**P-Reviewer:** Sipos F

**Received:** August 21, 2024

**Revised:** September 19, 2024

**Accepted:** October 12, 2024

**Published online:** December 15, 2024

**Processing time:** 82 Days and 22 Hours



**Zhong-Bao Shao, Ke He, Zhi Shi,** Cancer Minimally Invasive Therapies Centre, Guangdong Second Provincial General Hospital, Jinan University, Guangzhou 510632, Guangdong Province, China

**Zhong-Bao Shao, Yu-Bin Su, Zhi Shi,** Department of Cell Biology & Institute of Biomedicine, Guangdong Provincial Biotechnology & Engineering Technology Research Center, Guangdong Provincial Key Laboratory of Bioengineering Medicine, Genomic Medicine Engineering Research Center of Ministry of Education, MOE Key Laboratory of Tumor Molecular Biology, National Engineering Research Center of Genetic Medicine, State Key Laboratory of Bioactive Molecules and Druggability Assessment, College of Life Science and Technology, Jinan University, Guangzhou 510632, Guangdong Province, China

**Co-first authors:** Zhong-Bao Shao and Ke He.

**Corresponding author:** Zhi Shi, MD, PhD, Professor, Department of Cell Biology & Institute of Biomedicine, Guangdong Provincial Biotechnology & Engineering Technology Research Center, Guangdong Provincial Key Laboratory of Bioengineering Medicine, Genomic Medicine Engineering Research Center of Ministry of Education, MOE Key Laboratory of Tumor Molecular Biology, National Engineering Research Center of Genetic Medicine, State Key Laboratory of Bioactive Molecules and Druggability Assessment, College of Life Science and Technology, Jinan University, No. 601 Huangpu Avenue West, Guangzhou 510632, Guangdong Province, China. [tshizhi@jnu.edu.cn](mailto:tshizhi@jnu.edu.cn)

### Abstract

Colorectal cancer (CRC) ranks third in the number of cancers mainly because of the inability to diagnose it at an early stage. The pathogenesis of CRC is complicated, which is the result of the complex interaction of multiple genetic and environmental factors. Currently, one of the main treatments for CRC is chemotherapy. But the primary cause of CRC treatment failure is drug resistance. The expression of cyclin-dependent kinase 9 (CDK9) was correlated with elevated autophagy levels in colon cancer, and high expression of CDK9 indicates a poor prognosis in CRC. The incidence of autophagy and the expressions of Beclin 1 and ATP binding cassette transporter G2 are different in left and right colon cancer, and autophagy may be involved in the occurrence of chemotherapy resistance. In this article, the roles of CDK9, ATP binding cassette transporter G2 and Beclin 1 in CRC were elucidated, emphasizing the linkages among them and providing potential therapeutic targets of CRC.

**Key Words:** Cyclin-dependent kinase 9; ATP binding cassette transporter G2; Beclin 1; Colorectal cancer; Chemotherapy

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** The expression of cyclin-dependent kinase 9 (CDK9) was correlated with elevated autophagy levels in colon cancer, and high expression of CDK9 indicates a poor prognosis in colorectal cancer (CRC). The incidence of autophagy and the expressions of Beclin 1 and ATP binding cassette transporter G2 were different between left and right colon cancer. The roles of CDK9, ATP binding cassette transporter G2 and Beclin 1 in CRC were clarified, underlining the linkages among them and providing potential therapeutic targets of CRC.

**Citation:** Shao ZB, He K, Su YB, Shi Z. Crosslink among cyclin-dependent kinase 9, ATP binding cassette transporter G2 and Beclin 1 in colorectal cancer. *World J Gastrointest Oncol* 2024; 16(12): 4778-4781

**URL:** <https://www.wjgnet.com/1948-5204/full/v16/i12/4778.htm>

**DOI:** <https://dx.doi.org/10.4251/wjgo.v16.i12.4778>

## TO THE EDITOR

A clinical and translational study by Zheng *et al*[1], reported that the rate of autophagy and the expressions of Beclin 1 (BECN1) and ATP binding cassette transporter G2 (ABCG2) differed between left and right colon cancer tissues. Autophagy may be associated with chemotherapy resistance in colorectal cancer (CRC) patients. And cyclin dependent kinase 9 (CDK9) is highly expressed in CRC that can be used as a prognostic marker in CRC patients. This research could provide a theoretical basis for the exploration of CDK9 and autophagy inhibitors in combination therapy to enhance tumor cell sensitivity to chemotherapy.

CRC ranks third in the number of cancers mainly owing to the inability to diagnose it at an early stage[2]. The pathogenesis of CRC is complexed, which is the result of the complex interaction of a lot of genetic and environmental factors[3]. At present, one of the main treatments for CRC is chemotherapy. But the primary cause of CRC treatment failure is drug resistance[4]. Consequently, elucidating research into molecular mechanisms of drug resistance can be beneficial to develop new diagnostic or therapeutic strategies to overcome the challenges in the treatment of CRC.


## THE CROSSLINK AMONG CDK9, ABCG2 AND BECN1 IN CRC

ABCG2, as an important member of the ATP-binding cassette transmembrane transporter superfamily, plays a significant role in cancer multidrug resistance[5]. Several agents have been reported to be able to reverse ABCG2-mediated multidrug resistance in CRC cells by inhibiting the transporter activity of ABCG2[6,7]. Now, we are interested in the authors' new finding that the expression level of ABCG2 in right colon cancer was higher than that in paracarcinoma tissue, but the expression level of ABCG2 was not significantly different between left colon cancer and paracarcinoma tissue. These findings might be useful for gaining insight into the pathogenesis of left and right colon cancer and improving treatment strategies for CRC therapy.

Autophagy refers to a catabolic process in which macromolecular substances such as misfolded proteins and damaged organelles are transported to lysosomes for degradation[8]. It can prevent genome damage and induce cancer cell death. And on the other hand, autophagy is a pro-oncogenic mechanism that provides drug resistance to cancer cells and promotes cancer cell growth[9]. The sensitivity of cancer cells to chemotherapeutic drugs can be restored by the use of autophagy inhibitors, such as chloroquine, or by the knockdown of autophagy-related proteins, including BECN1, autophagy-related gene 7, and autophagy-related gene 10[10]. Currently, autophagy inhibitors are promising for cancer treatment. Some small molecule autophagy inhibitors have been discovered according to the autophagy process[10]. Recent research has revealed FDW028 (a novel FUT8 inhibitor) exhibits potent anti CRC effects by facilitating lysosomal degradation of CD276 through the chaperone-mediated autophagy pathway[11]. Erianin (a natural product) can induce autophagy-dependent ferroptosis and inhibit tumor growth and metastasis in KRAS<sup>G13D</sup> CRC[12]. Strigolactones are endogenous plant hormones that can act as a potential autophagy inhibitor by blocking autophagosome-lysosome fusion in HCT116 CRC cells[13]. BECN1, a key autophagy regulator, serves as a potential therapeutic target and is associated with chemotherapeutic resistance in cancers[14]. Previous studies have demonstrated that JAK2-dependent BECN1 phosphorylation may confer chemotherapy resistance in CRC[15]. Based on Zheng *et al's* research, the expression of BECN1 may be different between left and right colon cancer[1]. This research provided new ideas for further investigation on the drug resistance in CRC.

CDK family, a large class of serine/threonine protein kinases, plays a vital role in cell cycle progression and gene transcription regulation. There have been some reports on CDK inhibitors in the treatment of CRC. Zeng *et al*[16] proposed that CDK1 serves as a potential target for oxaliplatin-resistant CRC treatment. Lee *et al*[17] reported that the combination of palbociclib (CDK 4/6 inhibitor) and gedatolisib (phosphatidylinositol 3-kinase/mammalian target of





**Figure 1** The relationships between cyclin-dependent kinase 9, ATP binding cassette transporter G2, Beclin 1 and autophagy in colorectal cancers. CDK9: Cyclin-dependent kinase 9; BECN1: Beclin 1; ABCG2: ATP binding cassette transporter G2.

rapamycin dual inhibitor) has synergistic anti-proliferative effects in both wild-type and mutated CRC cell lines. In a recent study, Wang *et al*[18] revealed that CDK3, CDK5 and CDK8 functioned as potential diagnostic markers for CRC. These findings give rationale for the application of CDK inhibitors in CRC treatment. CDK9 is an important member of the CDK family that regulates the transcription of genes such as chemoresistant genes in tumors, and some CDK9 inhibitors have entered clinical trials in combination with other drugs[19]. According to Zheng *et al*[1], the expression of CDK9 is positively correlated with autophagy in colon cancer. This finding may provide valuable information for further research on targeting CDK9 as a therapeutic strategy for CRC. The relationships between CDK9, BECN1, ABCG2 and autophagy are shown in Figure 1.

## CONCLUSION

The expression of CDK9 was correlated with elevated autophagy levels in colon cancer. Additionally, the expressions of ABCG2 and BECN1 were different between left and right colon cancer patients. Targeting CDK9, ABCG2 and BECN1 might be potential therapeutic strategies for CRC.

## ACKNOWLEDGEMENTS

Thanks to all authors for their efforts in this work.

## FOOTNOTES

**Author contributions:** Shao ZB, He K, Su YB, and Shi Z contributed to this paper; Shi Z designed the overall concept and outline of the manuscript; Su YB contributed to the discussion of the manuscript; Shao ZB and He K contributed to the writing, and editing the manuscript, and review of literature, they are the co-first authors of this article.

**Supported by** the National Natural Science Foundation of China, No. 82272996; and the Science and Technology Program of Guangzhou, No. 202206010081.

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

**Country of origin:** China

**ORCID number:** Zhi Shi 0000-0002-8328-0305.

**S-Editor:** Wang JJ

**L-Editor:** A

**P-Editor:** Wang WB



## REFERENCES

- 1 **Zheng L**, Lu J, Kong DL. Expression of cyclin-dependent kinase 9 is positively correlated with the autophagy level in colon cancer. *World J Gastrointest Oncol* 2024; **16**: 314-330 [PMID: 38425408 DOI: 10.4251/wjgo.v16.i2.314]
- 2 **Zhang Y**, Wang Y, Zhang B, Li P, Zhao Y. Methods and biomarkers for early detection, prediction, and diagnosis of colorectal cancer. *Biomed Pharmacother* 2023; **163**: 114786 [PMID: 37119736 DOI: 10.1016/j.biopha.2023.114786]
- 3 **Ionescu VA**, Gheorghe G, Bacalbasa N, Chiotoroiu AL, Diaconu C. Colorectal Cancer: From Risk Factors to Oncogenesis. *Medicina (Kaunas)* 2023; **59** [PMID: 37763765 DOI: 10.3390/medicina59091646]
- 4 **Zhang L**, Lu X, Xu Y, La X, Tian J, Li A, Li H, Wu C, Xi Y, Song G, Zhou Z, Bai W, An L, Li Z. Tumor-associated macrophages confer colorectal cancer 5-fluorouracil resistance by promoting MRP1 membrane translocation via an intercellular CXCL17/CXCL22-CCR4-ATF6-GRP78 axis. *Cell Death Dis* 2023; **14**: 582 [PMID: 37658050 DOI: 10.1038/s41419-023-06108-0]
- 5 **Li W**, Zhang H, Assaraf YG, Zhao K, Xu X, Xie J, Yang DH, Chen ZS. Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies. *Drug Resist Updat* 2016; **27**: 14-29 [PMID: 27449595 DOI: 10.1016/j.drug.2016.05.001]
- 6 **Yu ZZ**, Xu BQ, Wang YY, Zhang PW, Shu YB, Shi Z. GSK2606414 Sensitizes ABCG2-Overexpressing Multidrug-Resistant Colorectal Cancer Cells to Chemotherapeutic Drugs. *Biomedicines* 2023; **11** [PMID: 38002103 DOI: 10.3390/biomedicines11113103]
- 7 **Liu K**, Chen Y, Shi XB, Xing ZH, He ZJ, Wang ST, Li YC, Liu WJ, Zhang PW, Yu ZZ, Mo XM, Shi XY, Chen ZS, Shi Z. Inhibiting the Activity of ABCG2 by KU55933 in Colorectal Cancer. *Recent Pat Anticancer Drug Discov* 2022; **17**: 387-395 [PMID: 35023460 DOI: 10.2174/1574892817666220112100036]
- 8 **Cao W**, Li J, Yang K, Cao D. An overview of autophagy: Mechanism, regulation and research progress. *Bull Cancer* 2021; **108**: 304-322 [PMID: 33423775 DOI: 10.1016/j.bulcan.2020.11.004]
- 9 **Kocaturk NM**, Akkoc Y, Kig C, Bayraktar O, Gozuacik D, Kutlu O. Autophagy as a molecular target for cancer treatment. *Eur J Pharm Sci* 2019; **134**: 116-137 [PMID: 30981885 DOI: 10.1016/j.ejps.2019.04.011]
- 10 **Chen JL**, Wu X, Yin D, Jia XH, Chen X, Gu ZY, Zhu XM. Autophagy inhibitors for cancer therapy: Small molecules and nanomedicines. *Pharmacol Ther* 2023; **249**: 108485 [PMID: 37406740 DOI: 10.1016/j.pharmthera.2023.108485]
- 11 **Wang M**, Zhang Z, Chen M, Lv Y, Tian S, Meng F, Zhang Y, Guo X, Chen Y, Yang M, Li J, Qiu T, Xu F, Li Z, Zhang Q, Yang J, Sun J, Zhang H, Zhang H, Li H, Wang W. FDW028, a novel FUT8 inhibitor, impels lysosomal proteolysis of B7-H3 via chaperone-mediated autophagy pathway and exhibits potent efficacy against metastatic colorectal cancer. *Cell Death Dis* 2023; **14**: 495 [PMID: 37537172 DOI: 10.1038/s41419-023-06027-0]
- 12 **Miao Q**, Deng WQ, Lyu WY, Sun ZT, Fan SR, Qi M, Qiu SH, Zhu YR, Lin JP, Chen MF, Deng LJ. Erianin inhibits the growth and metastasis through autophagy-dependent ferroptosis in KRAS(G13D) colorectal cancer. *Free Radic Biol Med* 2023; **204**: 301-312 [PMID: 37217090 DOI: 10.1016/j.freeradbiomed.2023.05.008]
- 13 **Yang ST**, Fan JB, Liu TT, Ning S, Xu JH, Zhou YJ, Deng X. Development of Strigolactones as Novel Autophagy/Mitophagy Inhibitors against Colorectal Cancer Cells by Blocking the Autophagosome-Lysosome Fusion. *J Med Chem* 2022 [PMID: 35852796 DOI: 10.1021/acs.jmedchem.2c00275]
- 14 **Prerna K**, Dubey VK. Beclin1-mediated interplay between autophagy and apoptosis: New understanding. *Int J Biol Macromol* 2022; **204**: 258-273 [PMID: 35143849 DOI: 10.1016/j.ijbiomac.2022.02.005]
- 15 **Hu F**, Song D, Yan Y, Huang C, Shen C, Lan J, Chen Y, Liu A, Wu Q, Sun L, Xu F, Hu F, Chen L, Luo X, Feng Y, Huang S, Hu J, Wang G. IL-6 regulates autophagy and chemotherapy resistance by promoting BECN1 phosphorylation. *Nat Commun* 2021; **12**: 3651 [PMID: 34131122 DOI: 10.1038/s41467-021-23923-1]
- 16 **Zeng K**, Li W, Wang Y, Zhang Z, Zhang L, Zhang W, Xing Y, Zhou C. Inhibition of CDK1 Overcomes Oxaliplatin Resistance by Regulating ACSL4-mediated Ferroptosis in Colorectal Cancer. *Adv Sci (Weinh)* 2023; **10**: e2301088 [PMID: 37428466 DOI: 10.1002/advs.202301088]
- 17 **Lee CL**, Cremona M, Farrelly A, Workman JA, Kennedy S, Aslam R, Carr A, Madden S, O'Neill B, Hennessy BT, Toomey S. Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer. *Cancer Biol Ther* 2023; **24**: 2223388 [PMID: 37326340 DOI: 10.1080/15384047.2023.2223388]
- 18 **Wang D**, Zhou Y, Hua L, Li J, Zhu N, Liu Y. CDK3, CDK5 and CDK8 Proteins as Prognostic and Potential Biomarkers in Colorectal Cancer Patients. *Int J Gen Med* 2022; **15**: 2233-2245 [PMID: 35250301 DOI: 10.2147/IJGM.S349576]
- 19 **Mandal R**, Becker S, Strebhardt K. Targeting CDK9 for Anti-Cancer Therapeutics. *Cancers (Basel)* 2021; **13** [PMID: 34062779 DOI: 10.3390/cancers13092181]



Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-3991568  
**E-mail:** [office@baishideng.com](mailto:office@baishideng.com)  
**Help Desk:** <https://www.f6publishing.com/helpdesk>  
<https://www.wjgnet.com>

